Quanterix Corporation (QTRX)
NASDAQ: QTRX · Real-Time Price · USD
7.05
+0.03 (0.43%)
At close: Jan 21, 2026, 4:00 PM EST
7.12
+0.07 (0.99%)
Pre-market: Jan 22, 2026, 7:19 AM EST
Quanterix Revenue
Quanterix had revenue of $40.23M in the quarter ending September 30, 2025, with 12.34% growth. This brings the company's revenue in the last twelve months to $130.20M, down -2.69% year-over-year. In the year 2024, Quanterix had annual revenue of $137.42M with 12.30% growth.
Revenue (ttm)
$130.20M
Revenue Growth
-2.69%
P/S Ratio
2.20
Revenue / Employee
$276,439
Employees
471
Market Cap
329.31M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 137.42M | 15.05M | 12.30% |
| Dec 31, 2023 | 122.37M | 16.85M | 15.96% |
| Dec 31, 2022 | 105.52M | -5.03M | -4.55% |
| Dec 31, 2021 | 110.56M | 24.18M | 27.99% |
| Dec 31, 2020 | 86.38M | 29.64M | 52.25% |
| Dec 31, 2019 | 56.73M | 19.10M | 50.76% |
| Dec 31, 2018 | 37.63M | 14.76M | 64.52% |
| Dec 31, 2017 | 22.87M | 5.29M | 30.08% |
| Dec 31, 2016 | 17.59M | 5.41M | 44.38% |
| Dec 31, 2015 | 12.18M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Viemed Healthcare | 254.79M |
| RxSight | 142.09M |
| Owlet | 99.64M |
| Delcath Systems | 79.60M |
| Sight Sciences | 76.05M |
| TriSalus Life Sciences | 40.21M |
| ClearPoint Neuro | 34.33M |
| Senseonics Holdings | 29.30M |
QTRX News
- 23 hours ago - Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer's Risk Profiling - Business Wire
- 5 days ago - Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 13 days ago - Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026 - Business Wire
- 4 weeks ago - Quanterix Announces Landmark Nature Study Redefining Alzheimer's Disease Neuropathology Prevalence - Business Wire
- 2 months ago - Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth - Business Wire
- 2 months ago - Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring - Business Wire
- 2 months ago - Quanterix Corporation (QTRX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Quanterix Releases Financial Results for the Third Quarter of 2025 - Business Wire